Recognition by the Swiss Biotech Association
for SOPHiA GENETICS’ Outstanding Contributions as a Leader in
Data-Driven Medicine
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space and a leader in data-driven medicine, was
honored to accept the Swiss Biotech Success Stories Award from the
Swiss Biotech Association. The Award recognizes SOPHiA GENETICS’
contributions in leading the way to democratizing data-driven
medicine.
Founded in Lausanne, Switzerland, SOPHiA GENETICS has been
working to democratize data-driven medicine for over a decade. As a
cloud-native software company, SOPHiA GENETICS provides a platform
driven by artificial intelligence and machine learning (known as
SOPHiA DDM™) that facilitates information-sharing and can lead to
breakthroughs for clinicians and researchers, particularly in
relation to life-threatening diseases such as cancer and rare
inherited disorders.
“We are honored to be recognized among so many other
distinguished organizations, including past winners Actelion and
Lonza, as one of the companies driving change in the complex
ecosystem of multimodal health data,” said Jurgi Camblong, CEO and
Co-Founder of SOPHiA GENETICS. “From inception, SOPHiA GENETICS has
been focused on democratizing data-driven medicine and has made
significant progress in doing so within the last decade. We are
proud to work with more than 750 institutions around the world and
have analyzed over 1.2 million genomic profiles with the SOPHiA
DDM™ Platform.”
Traditional medical data analysis in the lab is costly, time
intensive, siloed, and often simply not feasible in
small-to-medium-sized institutions. With SOPHiA GENETICS’
technology, healthcare professionals and researchers can combine
their experience and intuition with data insights and shared
knowledge from their peers to inform their decision-making.
By providing a more comprehensive look at medical information
through multiple sources, SOPHiA DDM™ enables the practice of
precision medicine, or data-driven medicine, in any hospital,
laboratory, or pharmaceutical company around the world. The
technology and data science teams behind the SOPHiA DDM™ Platform
are constantly working to develop new applications for the
examination of specific disease areas.
In the previous year, SOPHiA GENETICS launched innovative new
software solutions and fostered new partnerships that are helping
to deliver groundbreaking technology to medical institutions around
the world on a larger scale. Some of the most recent announcements
include:
- An expanded strategic partnership with AstraZeneca to apply
multimodal technology and expertise to the AstraZeneca oncology
portfolio;
- An expanded agreement with Memorial Sloan Kettering Cancer
Center (“MSK”), allowing SOPHiA GENETICS’ global network of
healthcare providers access to MSK’s proprietary comprehensive
liquid biopsy and tumor sequencing tests MSK-ACCESS® and
MSK-IMPACT®, powered with SOPHiA DDM™;
- A collaboration with Qiagen to pair QIAseq reagent technology
with the universal SOPHiA DDM™ Platform to enhance cancer and rare
disease analysis for next-generation sequencing (NGS) applications;
and
- A partnership with Agilent to offer a comprehensive solution
for cancer analysis.
“SOPHiA GENETICS is not only revolutionizing the way researchers
and clinicians are using data, but it is also breaking barriers to
make this practice more accessible to all,” said Michael Altorfe,
CEO, Swiss Biotech Association. “SOPHiA GENETICS’ approach to
healthcare is refreshing and it is for that reason that we
recognize it as a Swiss Biotech Success Story.”
The Swiss Biotech Success Stories Awards were launched in 2018
to illustrate how Swiss biotech companies help patients, improve
healthcare worldwide, and make a valuable and significant
contribution to the Swiss and global economies. Laureates are
individuals or groups who have earned extraordinary merits. Success
is broadly defined as scientific, translational, medical,
commercial, and other aspects that have a positive impact on the
biotech and life science industry and society in Switzerland and
the world.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn,
Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
About Swiss Biotech and the Swiss Biotech Association
Founded in 1998, the Swiss Biotech Association represents the
interests of the Swiss biotech industry. To support its members in
a competitive market, the Swiss Biotech Association works to secure
favorable framework conditions and facilitate access to talents,
novel technologies and financial resources. To strengthen and
promote the Swiss biotech industry, the Swiss Biotech Association
collaborates with numerous partners and life science clusters
globally under the brand Swiss Biotech™. For further information
visit swissbiotech.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230425005479/en/
Media: Kelly Katapodis kkatapodis@sophiagenetics.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024